C-Rad AB (publ) (CRAD-B.ST) Stock Analysis & Winston Score

C-Rad AB is a Swedish medical device company that makes equipment used in radiation therapy for cancer treatment. Its core products help hospitals position patients precisely before and during radiation sessions, so the beams hit tumors accurately and avoid healthy tissue. The company sells to hospitals and cancer clinics around the world. C-Rad earns money by selling hardware systems and software licenses, and it also generates recurring revenue through service contracts and software upgrades. The company operates globally, with a strong presence in Europe, North America, and Asia, and its roughly $1.1 billion market cap reflects its niche position in a specialized corner of the oncology equipment market. Its main competitive advantage is its focused expertise in patient positioning and surface-guided radiation therapy, a segment with relatively few dedicated players. The key growth driver is the rising global demand for cancer treatment, though the company faces risk from larger medical device giants that could expand into its niche with greater resources.